ProQR Therapeutics

We are ProQR Therapeutics, a biotechnology company dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses ADAR, the cell’s own editing machinery to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression. Axiomer® has the potential to yield a new class of medicines for both rare and prevalent diseases with unmet medical need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

ProQR is based in Leiden, the Netherlands, with offices in Cambridge, MA, USA. Since 2014 we are listed on the Nasdaq stock exchange (ticker: PRQR).